Cargando…
Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings
PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic disea...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071711/ https://www.ncbi.nlm.nih.gov/pubmed/32169115 http://dx.doi.org/10.1186/s40644-020-00300-7 |
_version_ | 1783506264875073536 |
---|---|
author | de Galiza Barbosa, Felipe Queiroz, Marcelo Araujo Nunes, Rafael Fernandes Costa, Larissa Bastos Zaniboni, Elaine Caroline Marin, José Flavio Gomes Cerri, Giovanni Guido Buchpiguel, Carlos Alberto |
author_facet | de Galiza Barbosa, Felipe Queiroz, Marcelo Araujo Nunes, Rafael Fernandes Costa, Larissa Bastos Zaniboni, Elaine Caroline Marin, José Flavio Gomes Cerri, Giovanni Guido Buchpiguel, Carlos Alberto |
author_sort | de Galiza Barbosa, Felipe |
collection | PubMed |
description | PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes. |
format | Online Article Text |
id | pubmed-7071711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70717112020-03-18 Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings de Galiza Barbosa, Felipe Queiroz, Marcelo Araujo Nunes, Rafael Fernandes Costa, Larissa Bastos Zaniboni, Elaine Caroline Marin, José Flavio Gomes Cerri, Giovanni Guido Buchpiguel, Carlos Alberto Cancer Imaging Review PSMA PET imaging was originally used to assess biochemical recurrence of prostate cancer (PCa), but its clinical use was promptly extended to detection, staging and therapy response assessment. The expanding use of PSMA PET worldwide has also revealed PSMA ligand uptake in diverse nonprostatic diseases, which raised questions about the specificity of this imaging modality. Although not very common initially, a growing number of pathologies presenting PSMA uptake on PET have been reported in the last few years, and a proper interpretation of PSMA PET imaging findings suddenly became challenging and, to some extent, confusing. Compared to cytoplasmic PSMA expression in nonprostatic cells, the molecular features of apical PSMA expression in PCa cells can help to distinguish these various conditions. Correlations of imaging findings to patient history, to the expected pattern of disease spread and mainly to computed tomography (CT) and/or magnetic resonance imaging (MRI) characteristics will reinforce the distinction of lesions that are more likely related to PCa from those that could lead to an incorrect diagnosis. The overall benefits of endothelial PSMA expression, which is associated with the neovasculature of malignant neoplasms, will be highlighted, stating the potential use of PSMA ligand uptake as a theranostic tool. This review aims to cover the collection of nonprostatic diseases, including benign and malignant tumors, in a didactic approach according to disease etiology, with discussion of bone-related conditions and inflammatory and infectious processes. BioMed Central 2020-03-14 /pmc/articles/PMC7071711/ /pubmed/32169115 http://dx.doi.org/10.1186/s40644-020-00300-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review de Galiza Barbosa, Felipe Queiroz, Marcelo Araujo Nunes, Rafael Fernandes Costa, Larissa Bastos Zaniboni, Elaine Caroline Marin, José Flavio Gomes Cerri, Giovanni Guido Buchpiguel, Carlos Alberto Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title | Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title_full | Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title_fullStr | Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title_full_unstemmed | Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title_short | Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings |
title_sort | nonprostatic diseases on psma pet imaging: a spectrum of benign and malignant findings |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071711/ https://www.ncbi.nlm.nih.gov/pubmed/32169115 http://dx.doi.org/10.1186/s40644-020-00300-7 |
work_keys_str_mv | AT degalizabarbosafelipe nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT queirozmarceloaraujo nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT nunesrafaelfernandes nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT costalarissabastos nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT zanibonielainecaroline nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT marinjoseflaviogomes nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT cerrigiovanniguido nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings AT buchpiguelcarlosalberto nonprostaticdiseasesonpsmapetimagingaspectrumofbenignandmalignantfindings |